The average revenue per capita in the 'Cold & Cough Remedies' segment of the otc pharmaceuticals market in Singapore was forecast to continuously increase between 2024 and 2029 by in total 15.4 U.S. dollars (+32.36 percent). After the ninth consecutive increasing year, the average revenue per capita is estimated to reach 63.03 U.S. dollars and therefore a new peak in 2029.
Data provided by Statista Market Insights are estimates.
Definition: The Cold and Cough market comprises over-the-counter natural and synthetic agents to relieve cough, expectorants and sore throat remedies, cold remedies and preparations against flu-like infections. Cough and cold medication includes medicines in the form of pills, syrups, lozenges, sprays, ointments and granulate for external and internal application. Not included are prescription medicines, preparations that are against the state law or are no explicit cold or cough drugs (e.g. painkillers). Among the top-selling medicines for cold and cough are nose sprays, Mucosolvan syrup, Grippostad C, Sinupret forte, Gelomyrtol, Dolo-Dobendan, Aspirin Complex, Bepanthen nose and eye cream, ACC Akut, Neo-Angin, Vick Vaporup, Isla Moos. It includes both products which are exclusively sold in pharmacies and products which can be purchased elsewhere. Sales by hospitals are not included.
Additional Information: The Cold and Cough market comprises revenues, average revenue per capita. Sales channels show online and offline revenue. Revenues include VAT. The market only displays B2C revenues, hence B2B and B2G revenues are not included. For more information on the data displayed, use the info button next to the boxes.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
Statista. (December 2, 2024). Revenue per capita of the cold & cough remedies market in Singapore from 2018 to 2029 (in U.S. dollars) [Graph]. In Statista. Retrieved December 22, 2024, from https://www.statista.com/forecasts/1196414/average-revenue-per-capita-cold-and-cough-remedies-singapore
Statista. "Revenue per capita of the cold & cough remedies market in Singapore from 2018 to 2029 (in U.S. dollars)." Chart. December 2, 2024. Statista. Accessed December 22, 2024. https://www.statista.com/forecasts/1196414/average-revenue-per-capita-cold-and-cough-remedies-singapore
Statista. (2024). Revenue per capita of the cold & cough remedies market in Singapore from 2018 to 2029 (in U.S. dollars). Statista. Statista Inc.. Accessed: December 22, 2024. https://www.statista.com/forecasts/1196414/average-revenue-per-capita-cold-and-cough-remedies-singapore
Statista. "Revenue per Capita of The Cold & Cough Remedies Market in Singapore from 2018 to 2029 (in U.S. Dollars)." Statista, Statista Inc., 2 Dec 2024, https://www.statista.com/forecasts/1196414/average-revenue-per-capita-cold-and-cough-remedies-singapore
Statista, Revenue per capita of the cold & cough remedies market in Singapore from 2018 to 2029 (in U.S. dollars) Statista, https://www.statista.com/forecasts/1196414/average-revenue-per-capita-cold-and-cough-remedies-singapore (last visited December 22, 2024)
Revenue per capita of the cold & cough remedies market in Singapore from 2018 to 2029 (in U.S. dollars) [Graph], Statista, December 2, 2024. [Online]. Available: https://www.statista.com/forecasts/1196414/average-revenue-per-capita-cold-and-cough-remedies-singapore